Migraine Headache Triggers and Nutritional Treatments
By Alan Gaby, MD.
- Dietary Factors
- Folic Acid
- Vitamin C
- Vitamin B12
- D and Calcium
- Review and Recommendations
A migraine is a throbbing, unilateral headache that is often associated with nausea, vomiting, photophobia, or an aura i.e., a transient disturbance of vision or of various aspects of neurological function. More than 10% of Americans suffer from migraines, with the prevalence in women being about 3 times that in men. The cause of migraine is not well understood, although it is thought to be due in part to vasoconstriction followed by reactive vasodilatation. The use of tobacco, oral contraceptives, or ergotamine a drug used to treat acute migraine episodes has been found to increase the frequency of migraines in some patients.
An array of different drugs are available to treat acute migraine episodes, including:
- Serotonin 5-HT1 agonists such as sumatriptan, naratriptan, and zolmitriptan
- Opioid analgesics; and dihydroergotamine and to prevent recurrences
- Valproic acid, beta blockers, and methysergide
While the acute treatments are often effective, they may cause adverse effects ranging from rebound headache to drug dependence to acute myocardial infarction. With regard to prophylaxis, even the most effective medications reduce mean migraine frequency by no more than 50%, and many of these drugs are associated with significant side effects. Safer and more effective ways of preventing and treating migraines are therefore needed.
In my experience, at least two-thirds of patients who comply with an appropriate regimen of dietary modification and nutritional supplements experience a substantial reduction in, or a complete cessation of, migraine attacks.
Reactive hypoglycemia/dysinsulinism. Abnormal blood glucose regulation appears to be a common cause of migraine. In a 1949 report, 11 patients with recurrent migraines associated with functional hyperinsulinism improved or experienced complete relief after consuming a high-protein, low-carbohydrate diet. In a later study, 74 patients who suffered from migraines in the mid-morning or mid-afternoon fasting state underwent a 5-hour glucose-tolerance test. Six patients 8.1% were classified as diabetic and 56-76% had a curve consistent with reactive hypoglycemia i.e., serum glucose less than 65 mg dl or a drop of 75 mg dl within 1 hour.
Following dietary therapy, restriction of refined sugar and consumption of 6 meals per day, all patients with a diabetic glucose curve and 56% of those with reactive hypoglycemia had an improvement of greater than 75% in the frequency and severity of migraines. Glucose dysregulation should be considered as a potential triggering factor in all migraine patients, par ticularly those who consume large amounts of refined carbohydrates or whose symptoms begin at a time of the day when blood glucose levels are typically lowest e.g., late morning or late afternoon. The evaluation and management of reactive hypoglycemia dysinsulinism is discussed in my book.
Caffeine is recognized in most review articles as a potential migraine trigger, but it is not generally assigned great importance. However, one practitioner observed that avoidance of caffeine frequently improved migraine patients’ responses to treatment and sometimes eliminated the need for long-term drug therapy. In my experience, avoiding caffeine is often beneficial and occasionally results in dramatic improvement in migraine sufferers. Caffeine consumption not only impairs blood glucose regulation, it also appears to trigger headaches by a mechanism unrelated to its effect on blood glucose control.
One investigator observed that a sudden salt load, par ticularly if taken on an empty stomach, can cause a migraine 6–12 hours later. Twelve patients with a history of migraines for many years were advised to avoid all salted snack foods such as pretzels, nuts, and potato chips before meals. During a 6-month follow-up period, migraines ceased completely in 3 patients and an additional 7 experienced a reduction in the frequency of attacks.
Food allergy appears to be one of the most common causes of migraines. As with many other chronic health conditions, the allergic reactions that provoke migraines are usually masked or hidden. While they cannot be reliably identified from a dietary history or skin tests, they can usually be “unmasked" by an elimination diet, followed by individual food challenges. The impor tance of food allergy as a cause of migraines has been documented repeatedly in the medical literature for more than 70 years, but most doctors remain unaware of this information. Tyramine and other compounds in food such as nitrates and monosodium glutamate are recognized in conventional medicine as precipitating factors see below, but it is uncommon for migraine patients to become headache-free solely by avoiding these substances.
Balyeat and Rinkel reported in 1930 and 1931 that food allergy is a frequent cause of migraine. Among 202 migraine patients treated by these investigators, avoidance of specific offending foods produced complete or near-complete symptom relief in 21.7% and par tial improvement in an additional 66.3% for a total response rate of 88%., Four other studies from the 1930s reported similar results.– Those studies included a total of 400 patients, and the frequency of par tial or complete relief obtained by avoiding allergenic foods ranged from 50.8% to 78%. One of the studies was conducted by Elmer L. DeGowin, coauthor of a classic textbook of physical diagnosis. Since then, numerous other investigators have repor ted that food allergy is a major factor in the etiology of migraine.– One study of adults and another of children provided detailed information and are described below.
Sixty patients with frequent migraines were studied. The mean duration of illness was 18 years for the women and 22 years for the men. Most of the patients had been using oral contraceptives, tobacco, or ergotamine and had failed to improve by discontinuing these substances. Each patient consumed an elimination diet for 5 days, consisting only of 2 low-risk foods usually lamb and pears and bottled spring water. Migraines disappeared within 5 days in most cases. Each patient then tested 1 to 3 common foods per day, looking for reactions. The mean number of foods that caused symptoms was 10 per patient range, 1–30. Foods that most frequently caused symptoms and/or pulse changes were wheat 78%; orange 65%; egg 45%; tea and coffee 40% each; chocolate and milk 37% each; beef 35%; corn, cane sugar, and yeast 33% each; mushrooms 30%; and peas 28%. When offending foods were avoided, all patients improved. The number of headaches in the group fell from 402 per month to 6 per month, and 85% of the patients became headache-free.
Eighty-eight children with severe, frequent migraines followed an elimination diet consisting typically of one meat lamb or chicken, one carbohydrate rice or potato, one fruit banana or apple, one vegetable brassica family, water, and vitamin and calcium supplements for 3– 4 weeks. Children who were headache-free or who experienced only 1 headache during the last 2 weeks of the diet reintroduced one additional food per week. If no reaction occurred, the food was added back to the diet, but foods that evoked symptoms were avoided again. Children who did not improve on the diet were offered a second oligoantigenic diet, with no foods in common with the first diet.
Seventy-eight children 88.6% recovered completely on the first or second oligoantigenic diet and 4 improved greatly, for a total improvement rate of 93%. Most patients reacted to several foods. Fifty-five different foods evoked symptoms, the most common of which were cow’s milk 31%; egg 27%; chocolate 25%; orange and wheat 24% each; benzoic acid 16%; cheese and tomato 15% each; tar trazine and rye 14% each; pork and fish 10% each; beef and corn 9% each; soy and tea 8% each; oats, goat’s milk, and coffee 7% each; and peanuts 6%. For ty of the patients who improved participated in double-blind, placebo-controlled food challenges, which confirmed the etiologic role of food allergy.
That at least some food-induced migraines are mediated by an allergic mechanism as opposed to a non-immunologically mediated mechanism is suggested by the fact that cromolyn sodium, a drug that blocks allergic reactions, prevented migraines in patients who ingested a known migraine-provoking food. Despite this large body of evidence implicating food allergy as a major cause of migraine, the consensus of 290 headache specialists in the United States who par ticipated in a survey was that diet is usually not an impor tant factor. Seventy-four percent of the respondents believed that foods are triggering factors in only 1–20% of migraine patients, whereas only 2% of the doctors estimated the frequency to be as high as 60 –80%.
Non-allergy-mediated food reactions
In contrast to masked allergies, the existence of which most patients are unaware, some patients are aware that ingestion of chocolate, cheese, citrus fruits, or alcohol particularly red wine precipitates migraines. The symptoms in these patients appear to be caused by reactions to vasoactive substances in foods or beverages, rather than by an allergic reaction. Compounds in foods and beverages that have been implicated as migraine triggers include tyramine,, phenylethylamine, and possibly histamine  and phenolic compounds.
The increased susceptibility that some people appear to have to these food-derived substances may be related to an inherent weakness in their capacity to metabolize them. Phenol sulfotransferase PST is an enzyme that exists in the body in 2 forms; PST-M which acts specifically on monoamines such as tyramine, and PST-P which inactivates cer tain phenolic compounds. Patients with migraines associated with a known food trigger had significantly lower platelet PST-P activity and non-significantly lower PST-M activity, compared with healthy controls and with migraine patients who had no known dietary triggers., Patients who developed migraines after eating chocolate also had significantly lower platelet monoamine oxidase activity, compared with controls.28 Monoamine oxidase metabolizes a number of different amines, including tyramine and phenylethylamine.
In addition, certain types of red wine were found to inhibit PST activity in vitro. Even after the wines were diluted 75-fold, they inhibited human platelet PST-P by a mean of 99% and human PST-M by 12%. If such inhibition occurs in vivo, then ingestion of these red wines could result in increased concentrations of various phenolic substances and amines, an effect that might explain why some red wines induce migraines. Avoiding cheese, chocolate, citrus fruits, and alcohol can significantly reduce the frequency of migraines in some patients. However, only 13% of patients in one study became headache-free simply by excluding those foods. That finding underscores the impor tance not only of avoiding obvious triggering agents, but of searching for hidden food allergens and other dietary factors as well.
There are numerous anecdotal repor ts of aspartame ingestion causing migraines or other types of headaches.– Some, but not all, controlled trials have confirmed that aspartame can trigger headaches. In a double-blind cross-over trial that included 11 migraine patients, more than twice as many migraines occurred while the patients were receiving aspartame 300 mg 4 times a day for 4 weeks than while they were receiving placebo mean number per 4 weeks, 3.55 vs. 1.55; In another study, 18 individuals who repor ted experiencing headaches after using aspar tame were randomly assigned to receive aspar tame 30 mg/kg of body weight per day or placebo for 7 days, and then the alternate treatment for an additional 7 days. Headaches occurred on 33% of the days during aspar tame treatment, compared with 24% of the days during placebo treatment.
A study funded by the NutraSweet Company the makers of aspartame showed that aspar tame did not trigger headaches more frequently than placebo in a group of people who had previously repor ted vascular headaches following aspar tame consumption. In that study, the subjects received a single challenge with aspartame 30 mg/kg of body weight, divided into 3 doses at 8 a.m., 10 a.m., and noon or placebo, and then the alternate treatment 2 days later. A limitation of that study is that a single aspar tame challenge may not be sufficient to induce a headache. It is possible that such headaches occur only after repeated aspar tame ingestion, or after a cer tain cumulative dose is reached. A potential limitation of all of the controlled trials is that aspar tame was administered in capsules or in freshly prepared cool solutions, rather than in soft drinks or other aspar tame containing foods or beverages. Aspartame in commercial products is said to undergo chemical changes on exposure to high temperatures or after storage for more than 2 months, and these degradation products may be responsible in part for the reported adverse effects of aspartame. Therefore, symptoms that occur after ingestion of aspartame-containing commercial products or hot drinks to which aspartame has been added may not be reproducible by challenging with aspartame in capsules or in freshly prepared cool solutions.
Based on the available evidence, aspartame should be considered a potential migraine trigger, and should be excluded during an elimination diet.
Nutritional supplements for prophylaxis
Several lines of evidence suggest that magnesium deficiency is involved in the pathogenesis of migraine. Cer tain factors that trigger migraines, including stress, menstruation, alcohol ingestion, and some diuretics, are known to cause magnesium depletion. Magnesium concentrations in erythrocytes, mononuclear cells, serum, and brain tissue measured by 31 P-magnetic resonance spectroscopy were significantly lower in both adults and children with migraines than in healthy controls.–
Experimental magnesium deficiency resulted in arterial spasm, spreading cor tical depression, central neurotransmitter release, and increased platelet aggregation, each of which is believed to play a role in the pathogenesis of migraine. Through its effect on ATP synthesis, magnesium is involved in mitochondrial energy production, which appears to be impaired in migraine patients , In addition, magnesium increased the activity of phenol sulfotransferases in vitro;  these enzymes play a role in detoxifying migraine precipitating compounds such as tyramine.
One practitioner administered 200 mg/day of magnesium from an amino acid chelate to more than 3,000 migraine patients mostly women of childbearing age, and reported a success rate of 80%. Since then, several clinical trials have evaluated the effectiveness of magnesium for migraine prophylaxis, and most have produced positive results.
Eighty-one migraine sufferers were randomly assigned to receive, in double-blind fashion, 600 mg/day of magnesium as trimagnesium dicitrate or placebo for 12 weeks. In weeks 9–12 the attack frequency was reduced by 41.6% in the magnesium group and by 15.8% in the placebo group compared with baseline for the difference in the change between groups. The reductions in mean duration of attacks and mean pain intensity were nonsignificantly greater in the magnesium group than in the placebo group. Adverse effects of magnesium were diarrhea in 18.6% of patients and gastric irritation in 4.7%. Twenty women with perimenstrual migraine were randomly assigned to receive, in double-blind fashion, 360 mg/day of magnesium or placebo, star ting on the 15th day of each cycle and continuing until menstruation. After 2 cycles, the Pain Total Index, which measures duration and intensity of migraines, was significantly lower in the magnesium group than in the placebo group. The mean number of days with headaches was reduced by 49% compared with baseline in the magnesium group, but there was no significant change in the placebo group.
One hundred eighty-eight children aged 3–17 years with at least 1 migraine per week during the previous 4 weeks were randomly assigned to receive, in double-blind fashion, magnesium 9 mg/kg of body weight per day, as magnesium oxide, given in 3 divided doses per day or placebo for 16 weeks. Compared with baseline, the number of days with at least 1 headache decreased significantly in the magnesium group and nonsignificantly in the placebo group. The percent decrease in headache frequency was non-significantly greater in the magnesium group than in the placebo group data not shown. Mean headache severity was significantly lower in the magnesium group than in the placebo group.
Sixty-nine patients with a history of migraines for at least 2 years were randomly assigned to receive, in double blind fashion, 243 mg of magnesium as magnesium aspar tate twice a day or placebo for 12 weeks. A positive response was defined as a reduction of at least 50% in the intensity or duration of migraine attacks. The propor tion of responders was 28.6% in the magnesium group and 29.4% in the placebo group. However, 33% of patients receiving magnesium and 11% of patients receiving placebo felt that their treatment was superior to previously used migraine medications. Several weaknesses of this study limit its usefulness. First, the study was underpowered: 146 patients were needed to detect a clinically meaningful difference in response rate between treatment groups, but only 61 patients completed the study. Second, more than half of the patients had apparently failed to respond to migraine-prevention drugs, suggesting that the study included a high propor tion of treatment-resistant patients. Third, the criteria for improvement a reduction of at least 50% in the duration or intensity of migraines were unusually strict. Only a few studies have used these criteria and most of them including studies of beta blockers, which are known to be effective showed no significant benefit from the treatment being tested.
Thus, magnesium supplementation appears to be a simple, safe, and effective way to reduce the frequency or severity of migraines, or both. In addition, there is evidence that intravenous magnesium can abort acute migraine episodes see below. Riboflavin. As the precursor of flavin adenine dinucleotide FAD, a coenzyme involved in the electron-transport chain, riboflavin plays a role in mitochondrial energy production, which appears to be impaired in migraine patients 46,48 Riboflavin at a dosage of 5 mg 3 times per day was repor ted in 1946 to be effective for migraine prophylaxis. Of 15 patients with simple migraine, 10 had a complete cessation of attacks and an additional 3 were markedly improved. Four of 4 patients with ophthalmic migraine had no fur ther attacks after star ting riboflavin. A dosage of 5 mg twice a day was found to be insufficient in some cases.
The apparent effectiveness of riboflavin was confirmed in a 1956 repor t. Of more than 100 migraine patients, the vast majority had a complete cessation of attacks after riboflavin supplementation. The dosage was 10 mg 3 times per day with meals for 6 months, followed by 10 mg/day indefinitely. Marked improvement was usually seen in less than a month. If a patient discontinued treatment, attacks would recur within a few months. These early observations were forgotten, and more than 40 years passed before a new generation of researchers, apparently unaware of the initial repor ts, again found riboflavin to be effective.
Forty-nine patients with recurrent migraines received 400 mg of riboflavin once a day for at least 3 months. The mean number of migraine attacks fell by 67% and mean migraine severity improved by 68%. One patient stopped treatment because of gastric intolerance that person was also taking small amounts of aspirin, but no other side effects were reported.
Twenty-three patients with recurrent migraines received 400 mg/day of riboflavin for 3 months, with an option to extend the treatment for an additional 3 months. Median headache frequency decreased from 4 days per month at baseline to 2 days per month after 3 and 6 months. The median headache duration decreased by 44%, from 50 hours at baseline to 28 hours at 3 and 6 months.
Fifty-five migraine patients were randomly assigned to receive, in double-blind fashion, 400 mg of riboflavin once a day or placebo for 3 months. In intent-to-treat analysis, riboflavin was superior to placebo in reducing attack frequency and headache days. The proportion of patients who experienced at least a 50% reduction in the number of headache days was 59% with riboflavin and 15% with placebo. Three minor adverse events occurred, 2 in the riboflavin group diarrhea and polyuria and 1 in the placebo group.
Fifty-two migraine patients were randomly assigned to receive, in double-blind fashion, daily treatment with a combination of 400 mg of riboflavin, 300 mg of magnesium, and 100 mg of fever few, or 2 “placebo" 25 mg of riboflavin for 3 months. The propor tion of patients who achieved a 50%-or-greater reduction in migraine frequency was 42% with combination therapy and 44% with low-dose riboflavin.
Both treatments reduced the frequency of migraines by approximately one-third. Mean headache severity and mean number of days with tension headache decreased with low-dose riboflavin, but not with combination therapy. The effect of low-dose riboflavin was greater than that reported for placebo in previous migraine trials. Each of the 3 compounds present in the combination treatment has been shown, when given alone, to reduce the incidence of migraines. While it is somewhat surprising that low-dose riboflavin was at least as effective as this combination treatment, it is possible that one or more of the substances in the combination product inter fered with the effect of the others, or that massive doses of riboflavin are less effective than more moderate doses. All of the studies that found riboflavin to be effective for migraine prophylaxis were conducted in adults. In a double-blind trial, supplementation with 200 mg/day of riboflavin did not decrease the frequency or severity of migraines in children mean age, 11 years. While some of the more recent trials used a very large dose of riboflavin 400 mg/day, moderate doses 15–30 mg/day also seem to be effective. Although high-dose riboflavin has not been associated with significant toxicity in short-term studies, it has the potential to act as a photosensitizer or to cause imbalances of other nutrients. Therefore, it would seem prudent to reserve high-dose riboflavin for patients who do not respond to moderate doses.
As a component of the electron transport chain, coenzyme Q10, CoQ10 plays a role in mitochondrial energy production, which appears to be impaired in migraine patients , In a study of 1,550 children and young adults with migraine, the serum concentration of CoQ10 was below the reference range in 32.9% of the patients. Two open-label trials , and one controlled trial  have found CoQ10 to be effective for migraine prophylaxis.
Thirty-two patients with a history of episodic migraines received 150 mg/day of CoQ10 for 3 months. During the last 2 months of treatment, compared with baseline, 61.3% of the patients had a greater than 50% reduction in the number of days per month with migraines. The mean number of days per month with migraines decreased by 59.8% 2.95 vs. 7.34 and the mean attack frequency decreased by 42% 2.81 vs. 4.85 per month. CoQ10 had no significant effect on headache intensity.
Forty-two migraine patients were randomly assigned to receive, in double-blind fashion, 100 mg of CoQ10 3 times per day or placebo for 4 months. The propor tion of patients who had a 50%-or-greater reduction in attack frequency during the four th month compared with baseline was 47.6% in the CoQ10 group and 14.3% in the placebo group. The mean reduction in attack frequency was 27.1% in the CoQ10 group and 2.1% in the placebo group for the difference in the change between groups. The mean duration and severity of migraines did not differ between groups.
As the precursor of nicotinamide adenine dinucleotide NAD, a coenzyme involved in the electron transport chain, niacinamide plays a role in mitochondrial energy production, which appears to be impaired in migraine patients. , While niacinamide has not been studied for migraine prophylaxis, 3 other nutrients that play a role in mitochondrial energy production magnesium, riboflavin, and coenzyme Q10 have each been found to be beneficial see above. It is therefore possible that niacinamide perhaps in doses of 500–1,000 mg/day would reduce the frequency or severity of migraines. In a case report, niacin supplementation successfully prevented attacks in a chronic migraine sufferer. However, that improvement may have been mediated by niacin’s vasodilatory effect, an action that is not shared by niacinamide. The dose of niacin was 375 mg of a sustained-release preparation twice a day, subsequently reduced to once a day.
Of 22 children aged 8–18 years with recurrent migraines without aura, 16 were found to have hyperhomocysteine mi a and one or more polymorphisms of the 5, 10- methylenetetrahydrofolate reductase MTHFR gene mainly homozygosity for 677CrT that are associated with reduced enzyme activity and moderate hyperhomocysteinemia. Those 16 children received 5 mg/day of folic acid for 6 months. Ten of the 16 children had a complete cessation of migraine attacks, 5 had a 75% reduction in attack frequency, and 1 had a 50% reduction in attack frequency. Of 3 patients who had been having daily migraines, all had a complete cessation of attacks.  Plasma homocysteine levels became normal in all 16 patients. The mechanism by which hyperhomocysteinemia might promote the development of migraines is not known.
In a double-blind trial, supplementation with folic acid in combination with vitamin B6 and vitamin B12 reduced the frequency and severity of migraines in adults with migraines accompanied by an aura.
Fifty-two patients mean age, 52 years with migraines accompanied by an aura were randomly assigned to receive, in double-blind fashion, daily B vitamins 2 mg of folic acid, 25 mg of vitamin B6, and 400 mg of vitamin B12 or placebo for 6 months. At baseline, the mean plasma homocysteine concentration was 10.8 mmol/L, which was 21% higher than the mean value for the general population. The mean plasma homocysteine level decreased by 39% in the active-treatment group compared with the change in the placebo group. The proportion of patients suffering from severe migraine disability fell from 61% to 30% in the active-treatment group, but did not change in the placebo group. Median headache frequency fell by 75% and median headache severity decreased by 25% in the active-treatment group; these values did not change in the placebo group. The reduction in migraine disability was restricted primarily to the 31 patients with the CC and CT MTHFR 677CrT genotypes. In that subgroup, the propor tion of patients suffering from severe migraine disability fell from 76% to 28%. In contrast, no significant reduction in severe migraine disability was seen in patients with the T T genotype. It was suggested that patients with the T T genotype may have needed a higher dose of folic acid, since patients with that genotype have an increased folate requirement. Alpha-lipoic acid. Alpha-lipoic acid plays a role in mitochondrial energy production, which appears to be impaired in migraine patients. In a small double-blind trial, supplementation with 600 mg of alpha-lipoic acid once a day for 3 months significantly reduced the frequency of migraine attacks comparing the third month with baseline. However, when compared with the change in the placebo group, the reduction in attack frequency in the ALA group did not reach statistical significance.
A 32-year-old man with a 6-year history of migraines found that attacks could be prevented by supplementing with 6g day of vitamin C. He then participated in a double-blind trial. Each day for 15 days he was randomly assigned to receive vitamin C or placebo. He experienced severe headaches on all of the placebo days and either no headaches or very minor ones on the vitamin C days. The mechanism of action of vitamin C and the frequency with which it might help other migraine patients are not known.
Migraines appear to be caused in par t by abnormalities of the serotonergic system, and serotonin receptor agonists triptans are effective in the treatment of acute migraines. L-Tryptophan is a naturally occurring precursor to serotonin. There is evidence that chronic migraine sufferers have a deficiency of serotonin in the brain, an abnormality that might be reversible with L-tryptophan supplementation. Two studies suggest that L-tryptophan may be an effective prophylactic agent for some migraine patients.
Eight migraine patients who had been refractory to conventional therapy received, in double-blind fashion, 500 mg of L-tryptophan every 6 hours or placebo L-leucine for 3 months, and then the alternate treatment for an additional 3 months. The mean headache index the number of attacks multiplied by the intensity was nonsignificantly lower by 32.8% with L-tryptophan than with placebo. In 4 of the 8 patients, headache indices were markedly lower with L-tryptophan than with placebo.
In a study published in Italian for which an English abstract is available, patients with migraines received, in double-blind fashion, 3 g 0day of L-tryptophan or placebo for one month. Those receiving L-tryptophan had significantly fewer migraines of significantly shor ter duration than did those receiving placebo.
While there are no clear guidelines regarding when to use L-tryptophan, a therapeutic trial might be wor thwhile for migraine patients with a history of depression, insomnia, or premenstrual syndrome.
L-5-Hydroxytryptophan 5-HTP, a metabolite of L-tryptophan and a direct precursor to serotonin, has also been evaluated for migraine prophylaxis. In 2 studies, 5-HTP at doses of 200 and 600 mg/day, respectively, appeared to be as effective as methysergide., However, 5-HTP was ineffective in children. For reasons that are explained in my book, L-tryptophan would seem to be preferable to 5-HTP as a therapeutic agent in most circumstances.
Co-administration of L-tryptophan or 5-HTP and drugs that increase serotonergic activity such as serotonin receptor agonists @triptans#, selective serotonin-reuptake inhibitors, amitriptyline, or monoamine oxidase inhibitors may increase both the efficacy and the toxicity of the drugs. If a patient is taking one of these medications, L-tryptophan should either be avoided completely particularly in the case of triptans or used with caution and in low doses perhaps 500 –1,000 mg/day, while monitoring for signs of serotonin excess serotonin syndrome. Fish oil. In 2 double-blind crossover trials published as abstracts that included a total of 23 patients with severe recurrent migraines, treatment with approximately 15 g 0day of fish oil for 6 weeks appeared to reduce the severity and possibly the frequency of headaches.,
In 2 other studies, fish oil reduced headache frequency compared with baseline, but not compared with the placebo, which was olive oil or olive oil/lactose. In one of these studies, which included 196 migraine patients, administration of 6 g 0day of fish oil for 16 weeks reduced mean headache frequency by 55%, as compared with a 45% reduction in the olive oil/lactose group for the difference in the change between groups.78 In the other trial, which included 27 adolescents with frequent migraines, treatment with fish oil providing 756 mg/day of eicosapentaenoic acid and 498 mg/day of docosahexaenoic acid for 2 months reduced mean headache frequency by 87%; however, the same 87% reduction was seen with olive oil. The improvements seen in these studies may have been due to a placebo effect, but they are also consistent with the possibility that both fish oil and olive oil are effective for migraine prophylaxis. Each of these oils has anti inflammatory activity, and inflammation has been implicated as a factor in the pathogenesis of migraine.
Twenty patients with a history of 2–8 migraine attacks per month for more than one year received 1 mg/day of hydroxocobalamin intranasally for 3 months. Half of the patients experienced at least a 50% reduction in migraine frequency. The mean attack frequency decreased from 4.7 per month prior to the study to 2.7 per month during treatment 43% reduction. Adverse reactions included nasal irritation n 5 6 and wheezing n 5 3. Vitamin B12 is believed to work by scavenging nitric oxide, which plays a role in the pathogenesis of migraines.
Concerns have been raised that long-term intranasal administration of vitamin B12 might damage pulmonary tissue. However, orally administered vitamin B12 raises serum cobalamin concentrations far less than does intranasal treatment. Periodic intramuscular injections of vitamin B12 might provide the best balance of efficacy and safety. A reasonable regimen would be 1,000 mg intramuscularly once a week for 4–6 weeks, continuing as needed if it appears to be effective.
Vitamin D and calcium
Two postmenopausal women with frequent and severe migraines and 2 premenopausal women with a history of migraines related to the menstrual cycle experienced a marked reduction in migraine frequency after treatment with a combination of vitamin D2 50,000 IU once a week for an unspecified period of time and calcium 1,000 –2,000 mg/day. One patient initially received 1,600 IU0day of vitamin D3 for 2 months and showed marked improvement before being switched to 50,000 IU0 week of vitamin D2 . In all cases, pretreatment 25-hydroxyvitamin D levels were below normal or near the lower end of the normal range., Potential adverse effects of high-dose vitamin D are discussed in my chapter.
Plasma levels and urinary excretion of melatonin were significantly lower in migraine patients than in controls. Thirty-two patients with episodic migraines received 3 mg/day of melatonin 30 minutes before bedtime for 3 months. Progressive improvement was seen during the course of the study. After 3 months, mean headache frequency had decreased by 60.5%, headache intensity had decreased by 51.4%, and headache duration had decreased by 55.6% for each comparison with baseline. The mechanism by which melatonin might prevent migraines is not known. There are no clear guidelines regarding when to consider the use of melatonin, but it might be most effective for migraine patients who have phase-shift insomnia.
Nutritional supplements for acute treatment
Parenteral magnesium was mentioned in the 1930s and 1940s as an effective treatment for migraine. More recently, several groups of investigators have evaluated intravenous magnesium as a treatment for acute migraine, and most of the results have been positive. For ty patients with an acute migraine received 1 g of magnesium sulfate in a 10% solution intravenously over 5 minutes. Fifteen minutes after the infusion, 35 patients 87.5% had at least a 50% reduction of pain, and 9 22.5% had complete relief. In 21 of the 35 patients who improved, the improvement persisted for 24 hours or more. Pain relief lasting at least 24 hours was seen in 18 of 21 patients 86% whose pretreatment serum ionized magnesium level was below 0.54 mmol/L, and in 3 of 19 patients 16% whose level was at or above 0.54 mmol/L. Twelve patients felt lightheaded for a few minutes upon sitting up after the infusion, but no other side effects were noted. For ty patients with an acute headache of which 27 were migraines received 1 g of magnesium sulfate in a 10% solution intravenously over 5 minutes. Pain resolved completely within 15 minutes in 32 patients 80%; in most of these cases the headache began to improve before the end of the infusion. Gastrointestinal symptoms, nausea, and photophobia were also completely eliminated in patients whose headaches were relieved. Of the 32 patients who improved, 18 were relieved of their headache for more than 24 hours. Of the 18 patients who had sustained relief, 16 89% had a low pretreatment serum ionized magnesium level. Of the 8 patients who had no relief, only 37.5% had a low ionized magnesium level.
Sixty patients with migraine with aura and 60 patients with migraine without aura were randomly assigned to receive, in double-blind fashion, intravenous magnesium sulfate 1 g diluted to 10 ml with 0.9% sodium chloride, given over 20 minutes or placebo 0.9% sodium chloride. In the group with aura, at 60 minutes, 36.7% of those receiving magnesium and 6.7% of those receiving placebo were pain free. At 24 hours, the respective percentages were 83.3% and 73.3% difference not significant. The severity of photophobia, phonophobia, and nausea were significantly less in the magnesium group than in the placebo group. In the group without aura, at 60 minutes, 23.3% of those receiving magnesium and 10% of those receiving placebo were pain-free difference not significant. At 24 hours, 66.7% of those receiving magnesium and 46.7% of those receiving placebo were pain-free. The severity of photophobia and phonophobia were significantly less and the severity of nausea was nonsignificantly less in the magnesium group than in the placebo group. Thus, intravenous magnesium sulfate relieved pain and associated symptoms in some patients with migraine with aura, but was somewhat less effective in patients with migraine without aura. Thirty patients with moderate or severe migraine attacks were studied. The first 15 patients received, in single-blind fashion, magnesium sulfate intravenously 1g diluted to 10 ml with 0.9% sodium chloride, given over 15 minutes, and the next 15 patients received placebo 0.9% sodium chloride. Patients in the latter group who did not improve after 30 minutes were treated with magnesium in the same fashion. Immediately after treatment and at 30 minutes and 2 hours, 86.6% of the patients in the magnesium group were pain-free, and the remaining 13.4% repor ted a reduction in pain severity. At all 3 time periods, accompanying symptoms such as nausea, vomiting, photophobia, and irritability had disappeared in each of the 14 patients who had experienced them. None of the patients given magnesium had a recurrence of pain within 24 hours. In the placebo group, no patient became pain-free for the difference between groups and only 6.7% experienced a reduction in pain. Accompanying symptoms disappeared in 3 patients 20% 30 minutes after placebo administration for the difference between groups. When patients in the placebo group were given magnesium, the response was similar to that in the magnesium group. Mild side effects occurred in 86.6% of the patients given magnesium; these included a burning sensation in the face and neck, flushing, and or a decrease in systolic blood pressure of 5–10 mm Hg.
Seventy-six adults with an acute migraine were randomly assigned to receive, in double-blind fashion, intravenous magnesium sulfate 2 g over 10 minutes or placebo. At 30 minutes, the magnesium group had improved by about 10 points more than the placebo group on a 100 point visual analogue scale for pain, but this difference was not statistically significant. The propor tion of patients who needed rescue medication at 30 minutes was lower in the magnesium group than in the placebo group 44% vs. 65%. However, the recurrence rate at 24 hours was similar in the 2 groups approximately 50%. Although the authors concluded that intravenous magnesium was not effective, there was a trend suggesting a modest beneficial effect. The relatively unimpressive results seen in this study may be explained in part by the fact that only 18% of the subjects had an aura. As mentioned previously, intravenous magnesium appears to be less effective in patients with migraine without aura than in those with aura. These studies suggest that intravenous magnesium can in some cases provide rapid and sustained relief from an acute migraine and its associated symptoms. The treatment is effective most often in patients whose migraine is accompanied by an aura, and in those with evidence of magnesium deficiency i.e., a low serum ionized magnesium concentration.
The Myers cocktail
I have administered the “Myers cocktail" a combination of magnesium, calcium, B vitamins, and vitamin C intravenously to half a dozen or more patients who presented on one or more occasions with an acute migraine. In most cases, complete symptom relief or marked improvement occurred within 2 minutes and did not return over the ensuing 24 hours. One patient with frequent migraines associated with multiple food and chemical sensitivities was treated for acute migraines more than 70 times over a 6-year period, and she responded well on all but a few occasions. It has been my clinical impression that this combination of nutrients is more effective than magnesium alone in the treatment of migraines. The Myers cocktail is described in my book.
One practitioner successfully used oral niacin to relieve his own migraines. At the onset of the aura, 300 –500 mg of niacin was chewed slightly and allowed to dissolve in the mouth.
Review - Recommendations
Note: These recommendations are classified as “primary" or “other," based on various factors including safety, efficacy, strength of the evidence, clinical experience, and cost.
1. Dietary modifications should be individualized. Potentially beneficial interventions include avoiding refined sugar, caffeine, and alcohol; avoiding excessive salt intake; identifying and avoiding allergenic foods; eliminating foods that contain tyramine, phenylethylamine, and other triggering agents such as chocolate, citrus fruits, some wines, and aged cheeses; avoiding symptom-evoking compounds such as aspar tame and monosodium glutamate; and eating oily fish 1–3 times a week as a source of fish oil.
2. Magnesium: 100 –300 mg twice a day for prophylaxis. For acute treatment, intravenous magnesium combined with calcium, B vitamins, and vitamin C frequently provides rapid relief.
3. Riboflavin: 15– 400 mg/day.
4. Coenzyme Q10 : 60 –300 mg/day.
5. Folic acid: 5 mg/day for patients with hyperhomocysteinemia.
6. A comprehensive nutritional program may include moderate amounts of vitamin C, vitamin D, niacinamide, vitamin B12, calcium, and fish oil. Higher doses of one or more of these nutrients, or supplementation with L-tryptophan or melatonin, may be considered for prophylaxis in patients who do not respond adequately to the primary recommendations.
7. Niacin: For acute treatment, 300 –500 mg chewed slightly and dissolved in the mouth.
8. Alpha-lipoic acid: 100 – 600 mg/day.
1. Grant ECG. Food allergy and migraine. Lancet 1979;2:358–359.
2. Wilkinson CF Jr. Recurrent migrainoid headaches associated with spontaneous hypoglycemia. American Journal of Medical Science 1949;218:209–212.
3. Dexter JD, Rober ts J, Byer JA. The five hour glucose tolerance test and effect of low sucrose diet in migraine. Headache 1978;18:91–94.
4. Werner A. Treatment of migraine. New England Journal of Medicine 2002;347:764.
5. Brainard JB. Salt load as a trigger for migraine. Minn Med 1976;59:232–233.
6. Balyeat RM, Brittain FL. Allergic migraine. Based on the study of fifty-five cases. American Journal of Medical Science 1930;180:212–221.
7. Balyeat RM, Rinkel HJ. Fur ther studies in allergic migraine: based on a series of two hundred and two consecutive cases. Annual International Medicine 1931;5: 713–728.
8. DeGowin EL. Allergic migraine: a review of sixty cases. Journal of Allergy 1932;3:557–566.
9. Vaughan WT. Allergic migraine. II. Analysis of a follow-up after five years. American Journal of Medical Science 1933;185:821–832.
10. Sheldon JM, Randolph TG. Allergy in migraine-like headaches. American Journal of Medical Science 1935;190:232–236.
11. Andresen AFR. Migraine, an allergic phenomenon. American Journal of Digestive Disease 1934;1:14 –17.
12. Randolph TG. Allergic headache: an unusual case of milk sensitivity. JAMA 1944;126:430 – 432.
13. Turnbull JA. Allergy as a factor in headaches. American Journal of Digestive Disease 1948;15: 16 –20.
14. Heymann H. Migraine and food allergy. South Africian Medical Journal 1952;26:949–950.
15. Unger AH, Unger L. Migraine is an allergic disease. Journal of Allergy 1952;23: 429– 440.
16. Unger AH. Allergy and headaches. Ann Allergy 1955;13:523–532.
17. Unger L, Cristol JL. Allergic migraine. Ann Allergy 1970;28:106 –110.
18. Speer F. Allergy and migraine: a clinical study. Headache 1971;11:63– 67.
19. Rapp DJ. Double-blind case repor t of chronic headache due to foods and air pollution. Ann Allergy 1978;40:289.
20. Ratner D, Shoshani E, Dubnov B. Milk protein-free diet for nonseasonal asthma and migraine in lactase-deficient patients. Israile Journal of Medical Science 1983;19: 806 –809.
21. Mansfield LE, Vaughan TR, Waller SF, et al. Food allergy and adult migraine: double-blind mediator confirmation of an allergic etiology. Ann Allergy 1985;55:126 –129.
22. Grant ECG. Food allergies and migraine. Lancet 1979;1:966 –969.
23. Egger J, Wilson J, Car ter CM, et al. Is migraine food allergy? A double-blind controlled trial of oligoantigenic diet treatment. Lancet 1983;2:865–869.
24. Monro J, Carini C, Brostoff J. Migraine is a food allergic disease. Lancet 1984;2:719–721.
25. Anonymous. Diet has minimal effect on the occurrence of migraine. American Family Physician 1984;30 4:321–322.
26. Moffett A, Swash M, Scott DF. Effect of tyramine in migraine: a double-blind study. Journal of Neurol Neurosurg Psychiatry 1972;35:496 – 499.
27. Hanington E, Harper AM. The role of tyramine in the aetiology of migraine and related studies on the cerebral and extracerebral circulations. Headache 1968;8:84 –97.
28. Sandler M, Youdim MBH, Hanington E. A phenylethylamine oxidising defect in migraine. Nature 1974;250:335–337.
29. Kalish GH. Headaches after red wine. Lancet 1981;1:1263.
30. Littlewood J, Glover V, Sandler M, et al. Platelet phenolsulphotransferase deficiency in dietary migraine. Lancet 1982;1:983–986.
31. Glover V, Littlewood J, Sandler M, et al. Biochemical predisposition to dietary migraine: the role of phenolsulphotransferase. Headache 1983;23:53–58.
32. Littlewood JT, Glover V, Sandler M. Red wine contains a potent inhibitor of phenolsulphotransferase. British Journal of Clinical Pharmacological 1985;19:275–278.
33. Johns DR. Migraine provoked by aspartame. New England Journal of Medicine 1986;315:456.
34. Steinmetzer RV, Kunkel RS. Aspar tame and headache. New England Journal of Medicine 1988; 318:1201.
35. Walton RG, Hudak R, Green-Waite RJ. Adverse reactions to aspartame: double-blind challenge in patients from a vulnerable population. Biological Psychiatry 1993;34:13–17.
36. Koehler SM, Glaros A. The effect of aspartame on migraine headache. Headache 1988;28:10 –13.
37. Van Den Eeden SK, Koepsell TD, Longstreth WT Jr, et al. Aspar tame ingestion and headaches: a randomized crossover trial. Neurology 1994;44:1787–1793.
38. Schiffman SS, Buckley CE III, Sampson HA, et al. Aspar tame and susceptibility to headache. New England Journal of Medicine 1987;317:1181–1185.
39. Rober ts HJ. Aspartame and headache. Neurology 1995;45:1631.
40. Altura BM. Calcium antagonist proper ties of magnesium: implications for antimigraine actions. Magnesium 1985;4:169–175.
41. Barbiroli B, Lodi R, Cor telli P, et al. Low brain free magnesium in migraine and cluster headache: an interictal study by in vivo phosphorus magnetic resonance spectroscopy on 86 patients. Cephalalgia 1997;17:254.
42. Mazzotta G, Sarchielli P, Alber ti A, Gallai V. Intracellular Mg11 concentration and electromyographical ischemic test in juvenile headache. Cephalalgia 1999;19:802–809.
43. Gallai V, Sarchielli P, Morucci P, Abbritti G. Red blood cell magnesium levels in migraine patients. Cephalalgia 1993;13:94 –98.
44. Soriani S, Arnaldi C, De Carlo L, et al. Serum and red blood cell magnesium levels in juvenile migraine patients. Headache 1995;35:14 –16.
45. Thomas J, Tomb E, Thomas E, Faure G. Migraine treatment by oral magnesium intake and correction of the irritation of buccofacial and cervical muscles as a side effect of mandibular imbalance. Magnes Research 1994;7:123–127.
46. Lodi R, Montagna P, Soriani S, et al. Deficit of brain and skeletal muscle bioenergetics and low brain magnesium in juvenile migraine: an in vivo 31 P magnetic resonance spectroscopy interictal study. Pediatric Research 1997;42:866 –871.
47. Ramadan NM, Halvorson H, Vande-Linde A, et al. Low brain magnesium in migraine. Headache 1989;29:590 –593.
48. Okada H, Araga S, Takeshima T, Nakashima K. Plasma lactic acid and pyruvic acid levels in migraine and tension-type headache. Headache 1998;38: 39– 42.
49. Baranczyk-Kuzma A, Szymczyk T. Extrahepatic sulfation of phenols. Bovine lung and intestinal phenol sulfotransferases. Biochemistry Pharmacological 1987;36: 3141–3146.
50. Weaver K. Magnesium and migraine. Headache 1990;30:168.
51. Peiker t A, Wilimzig C, Kohne-Volland R. Prophylaxis of migraine with oral magnesium: results from a prospective, multi-center, placebo-controlled and double-blind randomized study. Cephalalgia 1996;16:257–263.
52. Facchinetti F, Sances G, Borella P, et al. Magnesium prophylaxis of menstrual migraine: effects on intracellular magnesium. Headache 1991; 31: 298–304.
53. Wang F, Van Den Eeden SK, Ackerson LM, et al. Oral magnesium oxide prophylaxis of frequent migrainous headache in children: a randomized, double-blind, placebo-controlled trial. Headache 2003;43:601– 610.
54. Pfaffenrath V, Wessely P, Meyer C, et al. Magnesium in the prophylaxis of migraine —a double-blind, placebo-controlled study. Cephalalgia 1996;16: 436 – 440.
55. Smith CB. The role of riboflavin in migraine. Canadian Medical Association Journal of 1946;54: 589–591.
56. Gordon L. Riboflavin in migraine. Br Medical Journal of 1956;2:550 –551.
57. Schoenen J, Lenaer ts M, Bastings E. High-dose riboflavin as a prophylactic treatment of migraine: results of an open pilot study. Cephalalgia 1994;14: 328–329.
58. Boehnke C, Reuter U, Flach U, et al. High-dose riboflavin treatment is efficacious in migraine prophylaxis: an open study in a ter tiary care centre. European Journal of Neurol 2004;11:475– 477.
59. Schoenen J, Jacquy J, Lenaer ts M. Effectiveness of high-dose riboflavin in migraine prophylaxis. A randomized controlled trial. Neurology 1998;50: 466 – 470.
60. Maizels M, Blumenfeld A, Burchette R. A combination of riboflavin, magnesium, and fever few for migraine prophylaxis: a randomized trial. Headache 2004;44:885–890.
61. MacLennan SC, Wade FM, Forrest KML, et al. High-dose riboflavin for mi grai ne prophyl axi s i n chi l dren: a doubl e-bl i nd, randomi zed, pl acebo controlled trial. Journal of Child Neurol 2008;23:1300 –1304.
62. Hershey AD, Powers SW, Vockell ALB, et al. Coenzyme Q10 deficiency and response to supplementation in pediatric and adolescent migraine. Headache 2007;47:73–80.
63. Rozen TD, Oshinsky ML, Gebeline CA, et al. Open label trial of coenzyme Q10 as a migraine preventive. Cephalalgia 2002;22:137–141.
64. Sandor PS, Di Clemente L, Coppola G, et al. Efficacy of coenzyme Q10 in migraine prophylaxis: a randomized controlled trial. Neurology 2005;64:713– 715.
65. Velling DA, Dodick DW, Muir JJ. Sustained-release niacin for prevention of migraine headache. Mayo Clinical Proc 2003;78:770 –771.
66. Di Rosa G, Attina S, Spano M, et al. Efficacy of folic acid in children with mi grai ne, hyperhomocyst ei nemi a and MTHFR pol ymorphi sms. Headache 2007;47:1342–1344.
67. Lea R, Colson N, Quinlan S, et al. The effects of vitamin supplementation and MTHFR C677T genotype on homocysteine-lowering and migraine disability. Pharmacogenet Genomics 2009;19:422– 428.
68. Magis D, Ambrosini A, Sandor P, et al. A randomized double-blind placebo-controlled trial of thioctic acid in migraine prophylaxis. Headache 2007;47:52– 57.
69. Bali L, Callaway E. Vitamin C and migraine: a case repor t. New England Journal of Medicine 1978;299:364.
70. Salmon S, Fanciullacci M, Bonciani M, Sicuteri F. Plasma tryptophan in migraine. Headache 1978;17:238–241.
71. Kangasniemi P, Falck B, Langvik VA, Hyyppa MT. Levotryptophan treatment in migraine. Headache 1978;18:161–166.
72. Steardo L, Sorge F, Florio C. @L-tryptophan treatment in essential headache: preliminary data#. @Article in Italian#. Acta Neurologica 1977;32:613– 623.
73. Sicuteri F. The ingestion of serotonin precursors L-5-hydroxytryptophan and L-tryptophan improves migraine headache. Headache 1973;13:19–22.
74. Titus F, Davalos A, Alom J, Codina A. 5-Hydroxytryptophan versus methysergide in the prophylaxis of migraine. Randomized clinical trial. Eur Neurol 1986;25:327–329.
75. Santucci M, Cor telli P, Rossi PG, et al. L-5-Hydroxytryptophan versus placebo in childhood migraine prophylaxis: a double-blind crossover study. Cephalalgia 1986;6:155–157.
76. McCarren T, Hitzemann R, Smith R, et al. Amelioration of severe migraine by fish oil omega-3 fatty acids. American Journal of Clinical Nutrition 1985;41:874.
77. Glueck CJ, McCarren T, Hitzemann R, et al. Amelioration of severe migraine with omega-3 fatty acids: a double-blind, placebo-controlled clinical trial. American Journal of Clinical Nutrition 1986;43:710.
78. Pradalier A, Bakouche P, Baudesson G, et al. Failure of omega-3 polyunsaturated fatty acids in prevention of migraine: a double-blind study versus placebo. Cephalalgia 2001;21:818–822.
79. Harel Z, Gascon G, Riggs S, et al. Supplementation with omega-3 polyunsaturated fatty acids in the management of recurrent migraines in adolescents. Journal of Adolesc Health 2002;31:154 –161.
80. van der Kuy PHM, Merkus FWHM, Lohman JJHM, et al. Hydroxocobalamin, a nitric oxide scavenger, in the prophylaxis of migraine: an open, pilot study. Cephalalgia 2002;22:513–519.
81. Shinton NK, Singh AK. Vitamin B12 absorption by inhalation. British Journal of Haematol 1967;13:75–79.
82. Thys-Jacobs S. Alleviation of migraines with therapeutic vitamin D and calcium. Headache 1994;34:590 –592.
83. Thys-Jacobs S. Vitamin D and calcium in menstrual migraine. Headache 1994;34:544 –546.
84. Gagnier JJ. The therapeutic potential of melatonin in migraines and other headache types. Alternative Medical Review 2001;6:383–389.
85. Peres MFP, Zukerman E, da Cunha Tanuri F, et al. Melatonin, 3 mg, is effective for migraine prevention. Neurology 2004;63:757.
86. Schick A. The treatment of Meniere’s syndrome with magnesium salts. Ann Otol Rhinol Laryngol 1943;52:45–51.
87. Mauskop A, Altura BT, Cracco RQ, Altura BM. Intravenous magnesium sulphate relieves migraine attacks in patients with low serum ionized magnesium levels: a pilot study. Clinical Science 1995;89:633– 636.
88. Mauskop A, Altura BT, Cracco RQ, Altura BM. Intravenous magnesium sulfate rapidly alleviates headaches of various types. Headache 1996;36:154 – 160.
89. Bigal ME, Bordini CA, Tepper SJ, Speciali JG. Intravenous magnesium sulphate in the acute treatment of migraine without aura and migraine with aura. A randomized, double-blind, placebo-controlled study. Cephalalgia 2002;22:345– 353.
90. Demirkaya S, Vural O, Dora B, Topcuoglu MA. Efficacy of intravenous magnesium sulfate in the treatment of acute migraine attacks. Headache 2001;41:171–177.
91. Cete Y, Dora B, Er tan C, et al. A randomized prospective placebo controlled study of intravenous magnesium sulphate vs. metoclopramide in the management of acute migraine attacks in the Emergency Depar tment. Cephalalgia 2005;25:199–204.
92. Hal l JA. Enhancing niacin's effect for migraine. Cortlandt Forum 1991 July:46.
Author Alan Gaby is a medical doctor and expert in nutritional therapy, working in the greater Boston area, and author of the textbook, "Nutritional Medicine."
Headache Relief Topics
Explore connections between headaches and digestion.